Skip to main content

Advertisement

SpringerLink
Log in

TNF Inhibitors for Psoriasis and Psoriatic Arthritis

  • Psoriasis (J Wu, Section Editor)
  • Published:
Current Dermatology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

A growing body of research highlights the use of TNF inhibitors in the treatment of psoriasis and psoriatic arthritis. We aim to review the literature, compile psoriasis efficacy data for TNF inhibitors, and offer advice regarding the approach to treating this condition.

Recent Findings

The results of randomized placebo-controlled studies indicate that TNF inhibitors are efficacious and well tolerated in the treatment of psoriasis. There is a greater prevalence of anxiety, depression, cardiovascular disease, obesity, diabetes, hypertension, dyslipidemia, fatty liver disease, metabolic syndrome, and inflammatory bowel disease in psoriasis patients than in the general population. Severe psoriasis portends an increased risk of mortality.

Summary

Although patients with mild-to-moderate psoriasis do not have an increased mortality rate, the inherent inflammatory nature of psoriasis and its association with serious comorbid conditions may warrant the use of systemic medications, such as TNF inhibitors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Weger W. Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol [Internet]. 2010;160(4):810–20. doi:10.1111/j.1476-5381.2010.00702.x.

    Article  CAS  Google Scholar 

  2. Kirkham B. Tumor necrosis factor-alpha inhibitors: an overview of adverse effects [Internet]. [cited 2016 Dec 31]. Available from: http://www.uptodate.com/contents/tumor-necrosis-factor-alpha-inhibitors-an-overview-of-adverse-effects.

  3. Wong M, Ziring D, Korin Y, Desai S, Kim S, Lin J, et al. TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol [Internet]. 2008;126(2):121–36. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17916444.

    Article  CAS  Google Scholar 

  4. Chen Y-F, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess [Internet]. 2006;10(42):iii–v. xi–xiii, 1-229. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17049139.

    Google Scholar 

  5. • Felquer MLA, Soriano ER. New treatment paradigms in psoriatic arthritis. Curr Opin Rheumatol [Internet]. 2015;27(2):99–106. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00002281-201503000-00002. This is a review article that consolidates the treatment options for psoriatic arthritis, notably for certolizumab pegol.

    Article  CAS  Google Scholar 

  6. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet (London, England) [Internet]. 2000;356(9227):385–90. Available from: http://www.sciencedirect.com/science/article/pii/S0140673600025307.

    Article  CAS  Google Scholar 

  7. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med [Internet]. 2003;349(21):2014–22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14627786.

    Article  CAS  Google Scholar 

  8. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50(7):2264–72.

    Article  CAS  PubMed  Google Scholar 

  9. Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CEM, Nakanishi AM, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol [Internet]. 2005;152(6):1304–12. doi:10.1111/j.1365-2133.2005.06688.x.

    Article  CAS  Google Scholar 

  10. Paller AS, Siegfried EC, Langley RG, Gottlieb AB, Pariser D, Landells I, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med [Internet]. 2008;358(3):241–51. doi:10.1056/NEJMoa066886.

    Article  CAS  Google Scholar 

  11. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet (London, England) [Internet]. 2001;357(9271):1842–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11410193.

    Article  CAS  Google Scholar 

  12. Barker J, Hoffmann M, Wozel G, Ortonne J-P, Zheng H, van Hoogstraten H, et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol [Internet]. 2011;165(5):1109–17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21910713.

    Article  CAS  Google Scholar 

  13. Reich K, Nestle FO, Papp K, Ortonne J-P, Evans R, Guzzo C, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet [Internet]. 2005;366(9494):1367–74. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16226614

    Article  CAS  Google Scholar 

  14. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EHS, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum [Internet]. 2005;52(10):3279–89. doi:10.1002/art.21306.

    Article  CAS  Google Scholar 

  15. Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106–15.

    Article  PubMed  Google Scholar 

  16. Strober BE, Poulin Y, Kerdel FA, Langley RG, Gu Y, Gupta SR, et al. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study. J Am Acad Dermatol. 2011;64(4):671–81.

    Article  CAS  PubMed  Google Scholar 

  17. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, et al. Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum [Internet]. 2009;60(4):976–86. doi:10.1002/art.24403.

    Article  CAS  Google Scholar 

  18. •• Kavanaugh A, IB MI, Mease PJ, Krueger GG, Gladman DD, van der Heijde D, et al. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. Ann Rheum Dis [Internet]. 2013;72(11):1777–85. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23161902. This randomized control trial illustrates the clinical efficacy and safety findings of golimumab in psoriatic arthritis.

    Article  CAS  Google Scholar 

  19. Reich K, Ortonne J-P, Gottlieb AB, Terpstra IJ, Coteur G, Tasset C, et al. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab′ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br J Dermatol [Internet]. 2012;167(1):180–90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22413944.

    Article  CAS  Google Scholar 

  20. •• Mease PJ, Fleischmann R, Deodhar AA, Wollenhaupt J, Khraishi M, Kielar D, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis [Internet]. 2014;73(1):48–55. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23942868. This randomised trial summarizes the clinical efficacy of certolizumab pegol (200mg vs 400mg) vs placebo.

    Article  CAS  Google Scholar 

  21. Semble AL, Davis SA, Feldman SR. Safety and tolerability of tumor necrosis factor-α inhibitors in psoriasis: a narrative review. Am J Clin Dermatol [Internet]. 2014;15(1):37–43. Available from: http://link.springer.com/10.1007/s40257-013-0053-5.

    Article  Google Scholar 

  22. • Oliveira Mde FSP, Rocha Bde O, Duarte GV. Psoriasis: classical and emerging comorbidities. An Bras Dermatol. 2015;90(1):9. This review article summarizes the most recent comorbities associated with psoriasis.

    Article  PubMed  Google Scholar 

  23. Langan SM, Seminara NM, Shin DB, Troxel AB, Kimmel SE, Mehta NN, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol [Internet]. 2012;132(3):556–62. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0022202X15356712.

    Article  CAS  Google Scholar 

  24. • Tablazon ILD, Al-Dabagh A, Davis SA, Feldman SR. Risk of cardiovascular disorders in psoriasis patients. Am J Clin Dermatol [Internet]. 2013;14(1):1–7. Available from: http://link.springer.com/10.1007/s40257-012-0005-5. This review article summarizes the direct relationship between the risk of cardiovascular disease and the severity of psoriasis.

    Article  Google Scholar 

  25. Ni C, Chiu MW. Psoriasis and comorbidities: links and risks. Clin Cosmet Investig Dermatol [Internet]. 2014;7:119–32. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24790463.

    Google Scholar 

  26. • Onumah N, Kircik LH. Psoriasis and its comorbidities. J Drugs Dermatol [Internet]. 2012;11(5 Suppl):s5–10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22644770. This is a review article complementing reference #22 in summarizing the most recent comorbities associated with psoriasis.

    CAS  Google Scholar 

  27. Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X, et al. The risk of mortality in patients with psoriasis. Arch Dermatol [Internet]. 2007;143(12):1493–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18086997.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC, 27157-1071, USA

    Leah A. Cardwell, Brandy Sullivan, Emilia Baran, Elias Oussedik & Steven R. Feldman

  2. Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA

    Steven R. Feldman

  3. Department of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA

    Steven R. Feldman

Authors
  1. Leah A. Cardwell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brandy Sullivan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Emilia Baran
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elias Oussedik
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Steven R. Feldman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Leah A. Cardwell.

Ethics declarations

Conflict of Interest

Steven Feldman declares research, speaking, and/or consulting support from a variety of companies including Galderma, GSK/Stiefel, Almirall, Leo Pharma, Baxter, Boeringer Ingelheim, Mylan, Celgene, Pfizer, Valeant, Taro, Abbvie, Cosmederm, Anacor, Astellas, Janssen, Lilly, Merck, Merz, Novartis, Regeneron, Novan, Parion, Qurient, National Biological Corporation, Caremark, Advance Medical, Sun Pharma, Suncare Research, Informa, UpToDate, and National Psoriasis Foundation. Dr. Feldman also consults for others through Guidepoint Global, Gerson Lehrman, and other consulting organizations. Dr. Feldman is founder and majority owner of www.DrScore.com. I am a founder and part owner of Causa Research, a company dedicated to enhancing patients’ adherence to treatment.

Leah A. Cardwell, Brandy Sullivan, Emilia Baran, and Elias Oussedik declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Funding

The Center for Dermatology Research is supported by an unrestricted educational grant from Galderma Laboratories, L.P.

Additional information

This article is part of the Topical Collection on Psoriasis

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cardwell, L.A., Sullivan, B., Baran, E. et al. TNF Inhibitors for Psoriasis and Psoriatic Arthritis. Curr Derm Rep 6, 113–120 (2017). https://doi.org/10.1007/s13671-017-0174-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13671-017-0174-9

Keywords

Search

Navigation